Pioneering The Development of Novel Precision Oncology Drugs Targeting Stress Support Pathways
Ribon is a clinical stage biopharmaceutical company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways using our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform.
Learn More
Our Proprietary BEACON+ Platform
We have created our proprietary BEACON+ platform to unlock the biochemical roles of NAD+-utilizing enzymes and to discover and develop small molecules for the treatment of cancer.
Learn More
RBN-2397 – PARP7 Inhibitor
Developing our lead product candidate, RBN-2397, as a potent, selective and orally available small molecule inhibitor of the monoPARP, PARP7, for the treatment of solid tumors.
Learn More
Cambridge, MA
Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting
Learn More